AbbVie

Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System
Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System
Forbes
Humira
AbbVie
biosimilars
FDA
Flag link:
J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey
J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey
Fierce Pharma
JNJ
AbbVie
Sanofi
Turkey
competition
Flag link:
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval
BioSpace
AbbVie
Teliso-V
antibody-drug conjugate
non-small cell lung cancer
Flag link:
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Medical Marketing and Media
biotech stocks
AbbVie
Immunogen
M&A
Flag link:
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Fierce Pharma
AbbVie
M&A
antibody-drug conjugate
Immunogen
Elahere
ovarian cancer
Flag link:
AbbVie cues up filing for c-Met ADC in lung cancer
AbbVie cues up filing for c-Met ADC in lung cancer
Pharmaphorum
AbbVie
Teliso-V
clinical trials
lung cancer
Flag link:
AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
Fierce Pharma
AbbVie
Rinvoq
patents
legal
Sandoz
Sun Pharma
Intas Pharmaceuticals
Flag link:
AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study
AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study
BioSpace
AbbVie
Ubrelvy
ubrogepant
migraines
clinical trials
Flag link:
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Medical Marketing and Media
Boehringer Ingelheim
AbbVie
Skyrizi
DTC advertising
pharma advertising
Flag link:
FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars
FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars
Dermatology Times
Samsung Bioepis
Organon
FDA
AbbVie
Humira
biosimilars
Flag link:
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
Fierce Pharma
FTC
Orange Book
patents
AbbVie
AstraZeneca
Boehringer Ingelheim
Flag link:
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost
AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost
Investors Business Daily
AbbVie
earnings
aesthetics
Humira
biosimilars
Flag link:
AbbVie and Lupus Therapeutics partner for SLE trial recruitment
AbbVie and Lupus Therapeutics partner for SLE trial recruitment
Clinical Trials Arena
AbbVie
Lupus Therapeutics
systemic lupus erythematosus
lupus
Rinvoq
clinical trials
Flag link:
Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Fierce Pharma
Takeda
AbbVie
Shire
M&A
legal
Flag link:
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease
Fierce Pharma
AbbVie
Akyrizi
JNJ
Stelara
Crohn's Disease
Flag link:
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
Clinical Trials Arena
AbbVie
clinical trials
Rinvoq
atopic dermatitis
Flag link:
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
Generics Bulletin
Pfizer
Humira
biosimilars
adalimumab
AbbVie
interchangeability
FDA
Flag link:
Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin
Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin
Medical Marketing and Media
AbbVie
M&A
Mitokinin
Parkinson's Disease
Flag link:
Allergan Aesthetics invests in women’s career trajectories to close STEM gap
Allergan Aesthetics invests in women’s career trajectories to close STEM gap
Medical Marketing and Media
AbbVie
Allergan Aesthetics
women
STEM
Flag link:

Pages